Great post, buildit. I agree with a lot, especially with your comments about the S1 always being part of the plan. In the last 12 months, there has been numerous statements regarding pending financing of which none have actually occurred. I don’t mean the dilutive financings that did occur last January, but proclamations in various conference calls. I hope this is different. Although I’m NOT a shareholder celebrating Generex raising 3 years of financing from the bully board when that’s not needed to get rid of the going concern. The plan, as we were told over and over, was that Veneto and a couple of these companies were to immediately bring revenue. And not to raise significant money until on a national exchange. Personally, I think one reason the share price has taken a beating is due to the Veneto deal not being what was advertised as we see in the 10 k. And their legal issues were well known. I’m hoping the pending Q gives credence to the Pantheon/ MediSource deals.
(4)
(0)
Generex Biotechnology Corp. (GNBTQ) Stock Research Links